Phase 2 Trial (POLA Study) of lurbinectedin plus olaparib in patients with advanced solid tumors: results of efficacy, tolerability, and the translational study

Poveda, Andrés; López-Reig, Raquel; Oaknin, Ana; Redondo Sánchez, Andrés; Rubio, Maria Jesús; Guerra, Eva; Fariñas-Madrid, Lorena; Gallego, Alejandro; Rodriguez-Freixinos, Víctor; Fernandez-Serra, Antonio; Juan, Oscar; Romero, Ignacio; López Guerrero, José Antonio

UAM_Biblioteca

Autor (es)

Poveda, Andrés; López-Reig, Raquel; Oaknin, Ana; Redondo Sánchez, Andrés

; Rubio, Maria Jesús; Guerra, Eva; Fariñas-Madrid, Lorena; Gallego, Alejandro; Rodriguez-Freixinos, Víctor; Fernandez-Serra, Antonio; Juan, Oscar; Romero, Ignacio; López Guerrero, José Antonio

Entidad

UAM. Departamento de Medicina

Editor

MDPI

Fecha de edición

2022-02-12

Cita

Cancers 14.4 (2022): 915

ISSN

2072-6694

DOI

10.3390/cancers14040915

Versión del editor

https://doi.org/10.3390/cancers14040915

Materias

Endometrial cancer; Genomic instability; Lurbinectedin; Olaparib; Ovarian cancer; Medicina

URI

http://hdl.handle.net/10486/703782

Derechos

Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional.

Mostrar el registro completo del ítem

Lista de ficheros

Nombre

9048687.pdf

Tamaño

1.607Mb

Formato

PDF

Google™ Scholar:Poveda, Andrés - López-Reig, Raquel - Oaknin, Ana - Redondo Sánchez, Andrés - Rubio, Maria Jesús - Guerra, Eva - Fariñas-Madrid, Lorena - Gallego, Alejandro - Rodriguez-Freixinos, Víctor - Fernandez-Serra, Antonio - Juan, Oscar - Romero, Ignacio - López Guerrero, José Antonio

Lista de colecciones del ítem

Producción científica en acceso abierto de la UAM [16522]

UAM_Biblioteca

Phase 2 Trial (POLA Study) of lurbinectedin plus olaparib in patients with advanced solid tumors: results of efficacy, tolerability, and the translational study

Autor (es)

Entidad

Editor

Fecha de edición

Cita

ISSN

DOI

Versión del editor

Materias

URI

Derechos

Lista de ficheros

Lista de colecciones del ítem

Registros relacionados

Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients ﻿

A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial ﻿

Molecular characterization and clinical impact of TMPRSS2-ERG rearrangement on prostate cancer: comparison between FISH and RT-PCR ﻿

Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients

A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial

Molecular characterization and clinical impact of TMPRSS2-ERG rearrangement on prostate cancer: comparison between FISH and RT-PCR